Summary

The global protein therapeutics market size reached US$ 345.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 603.5 Billion by 2032, exhibiting a growth rate (CAGR) of 6.2% during 2024-2032. The increasing prevalence of chronic diseases such as cancer, diabetes, cardiovascular diseases, and autoimmune disorders, the rapid technological advancements in protein engineering, the expanding biopharmaceutical industry, and the widespread product applications in diverse therapeutic areas are some factors propelling the market.

Protein therapeutics is a class of medical treatments utilizing proteins or peptides to prevent, manage, or cure diseases. These therapeutics are designed to target specific molecules or pathways within the body, providing a highly targeted approach to treatment. They offer innovative solutions for a wide range of conditions, including cancer, autoimmune disorders, genetic diseases, and more. They can be derived from natural sources or produced through recombinant DNA technology, allowing for the development of highly specific and potent therapies. These therapeutic proteins can take various forms, including monoclonal antibodies, growth factors, enzymes, and cytokines. They interact with specific receptors or molecules in the body, modulating cellular processes, inhibiting or stimulating immune responses, or directly targeting disease-causing agents. The advantages of protein therapeutics lie in their high specificity, potency, and low toxicity. They often offer improved efficacy and fewer side effects than traditional small-molecule drugs. They have significantly advanced the field of medicine, providing novel treatment options and improving patient outcomes across various diseases.
The global market is majorly driven by the increasing focus on personalized medicine. In line with this, the rising research and development activities and the expanding healthcare infrastructure are significantly contributing to the market. Furthermore, the advancements in manufacturing processes are expected to fuel the market. Apart from this, the breakthroughs in genetic engineering, protein synthesis, and production technologies have enhanced the efficiency and effectiveness of protein therapeutics, positively influencing the market. Moreover, the growing prevalence of chronic diseases such as cancer, diabetes, cardiovascular disorders, and autoimmune diseases is catalyzing the market. Besides, the widespread applications of protein therapeutics in oncology are stimulating the market. Additionally, the rapid innovations in drug delivery systems have improved the delivery of protein therapeutics, enhancing their efficacy and patient compliance. Novel delivery methods such as sustained-release formulations, nanoparticles, and targeted drug delivery systems are driving the market growth by increasing the therapeutic potential of protein drugs.
Protein Therapeutics Market Trends/Drivers:
Growing biopharmaceutical research and development investments
Biopharmaceutical companies and research institutions are increasingly focusing on the development of protein-based drugs due to their high specificity, efficacy, and targetability. The rise in R&D investments in the biopharmaceutical sector is fueling advancements in protein therapeutics. These investments support research activities related to protein engineering, drug discovery, and formulation optimization, leading to the development of novel and improved protein therapeutics. Furthermore, the substantial funds allocated to R&D enable researchers to explore new therapeutic targets, optimize protein structures for enhanced activity, and conduct extensive preclinical and clinical trials. These efforts contribute to the expansion of the market by introducing innovative treatments for various diseases. Moreover, the growing R&D investments facilitate the scaling-up of production processes for protein therapeutics, making them more accessible and cost-effective. This enables increased commercialization and market penetration of protein-based drugs.
Expansion of biosimilars
The expansion of the biosimilars market is significantly contributing to the market. Biosimilars are biologic drugs that are highly similar to approved reference protein therapeutics. As patents for several blockbuster biologics expire, the market for biosimilars is expanding rapidly. The availability of biosimilars provides cost-effective alternatives to expensive protein therapeutics, making them more accessible to patients and healthcare systems. This increased affordability enhances patient access to necessary treatments, driving market growth. Furthermore, the introduction of biosimilars fosters competition in the market. Competition leads to price reductions, encouraging market expansion and creating opportunities for biosimilar manufacturers and reference protein therapeutics companies to innovate and improve their products. Moreover, the regulatory frameworks and guidelines for biosimilars have become more established and streamlined, providing a clear pathway for their development and approval. This has instilled confidence in the healthcare community and resulted in increased biosimilar adoption. As the biosimilars market expands, it stimulates further research and development efforts in protein therapeutics. Manufacturers strive to develop more advanced and differentiated biosimilars, creating a positive outlook for the market.
Rising aging population
The rising aging population is positively influencing the market. As the global population ages, there is a higher prevalence of age-related diseases and conditions such as Alzheimer's disease, Parkinson's disease, macular degeneration, and osteoporosis. Protein therapeutics are being developed and utilized to address these specific health challenges the aging population faces. Furthermore, protein therapeutics offer targeted treatment options for age-related diseases, providing improved efficacy and reduced side effects as compared to traditional therapies. They can target specific molecular pathways and address the underlying mechanisms of these diseases, thereby improving patient outcomes and quality of life. Moreover, the increasing product demand among the aging population is driving market growth. Pharmaceutical companies and research institutions are investing in the development of novel protein therapeutics to meet the specific needs of this demographic. Additionally, the growing aging population creates a larger market for protein therapeutics, prompting manufacturers to expand their product portfolios and increase production. This, in turn, leads to a wider availability of protein therapeutics and further drives market growth.

Protein Therapeutics Industry Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global protein therapeutics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on product, therapy area, and function.
Breakup by Product:

• Monoclonal Antibodies (mAbs)
• Human Insulin
• Erythropoietin
• Clotting Factors
• Fusion Protein
• Others

Monoclonal Antibodies (mAbs) dominates the market
The report has provided a detailed breakup and analysis of the market based on product. This includes monoclonal antibodies (mAbs), human insulin, erythropoietin, clotting factors, fusion protein, and others. According to the report, monoclonal antibodies (mAbs) represented the largest segment.
Monoclonal antibodies (mAbs) are extensively used to treat cancer, autoimmune disorders, and inflammatory diseases. The increasing prevalence of these conditions, coupled with advancements in antibody engineering and production technologies, drives the demand for mAbs and contributes to the market growth.
On the other hand, human insulin is a vital protein therapeutic for managing diabetes. With the rising incidence of diabetes worldwide, the demand for insulin and insulin analogs is increasing, leading to market growth in this segment. Moreover, erythropoietin (EPO) is another important therapeutic protein stimulating red blood cell production. It is used to treat anemia, particularly in patients with chronic kidney disease and cancer undergoing chemotherapy. The expanding patient pool requiring EPO therapy is driving the growth of this segment.
Besides this, the clotting factors are proteins essential for blood clotting. They are used to manage bleeding disorders such as hemophilia. The growing awareness, diagnosis, and treatment of hemophilia fuel the demand for clotting factors and contribute to the market. In addition, fusion proteins, which combine two or more functional protein domains, have gained significant attention in the development of innovative therapeutics. They offer unique treatment approaches for various diseases, including cancer and autoimmune disorders, thus driving the market in this segment.
Breakup by Therapy Area:
• Metabolic Disorders
• Immunological Disorders
• Hematological Disorders
• Cancer
• Hormonal Disorders
• Genetic Disorders
• Others

Metabolic Disorders holds the largest share of the market
A detailed breakup and analysis of the market based on the therapy area have also been provided in the report. This includes metabolic disorders, immunological disorders, hematological disorders, cancer, hormonal disorders, genetic disorders, and others. According to the report, metabolic disorders accounted for the largest market share.
Metabolic disorders encompass conditions such as diabetes, obesity, and hypercholesterolemia. Protein therapeutics, such as insulin for diabetes management, are crucial in treating and controlling these disorders. The rising prevalence of metabolic disorders, coupled with the increasing demand for targeted and effective treatments, is driving the growth of the market in this segment.
On the contrary, immunological disorders, including autoimmune diseases and inflammatory conditions, represent another significant therapy area for protein therapeutics. Monoclonal antibodies and other protein-based drugs modulate the immune system and target specific disease pathways. The growing incidence of immunological disorders and the expanding range of approved protein therapeutics for these conditions are driving the market.
In addition, cancer remains one of the primary drivers of the market. Protein-based therapies, including monoclonal antibodies, antibody-drug conjugates, and immune checkpoint inhibitors, have revolutionized cancer treatment. The increasing incidence of cancer globally, coupled with the development of targeted therapies and immunotherapies, is propelling the growth of the market in oncology.
Breakup by Function:
• Enzymatic and Regulatory Activity
• Special Targeting Activity
• Vaccines
• Protein Diagnostics

A detailed breakup and analysis of the market based on the function have also been provided in the report. This includes enzymatic and regulatory activity, special targeting activity, vaccines, and protein diagnostics.
Protein therapeutics with enzymatic and regulatory activity are vital in modulating biological processes and metabolic pathways. These proteins act as enzymes, receptors, or signaling molecules, offering therapeutic benefits in various diseases. The development of novel protein therapeutics with specific enzymatic or regulatory functions drives market growth in this segment.
Furthermore, special targeting activity refers to protein therapeutics targeting certain cells, tissues, or molecular targets. Monoclonal antibodies and antibody-drug conjugates are examples of protein therapeutics with special targeting activity. They can precisely recognize and bind to specific molecules or cells, providing highly targeted therapies. The increasing demand for targeted treatments in conditions such as cancer and autoimmune diseases fuels the growth of protein therapeutics in this segment.
Moreover, vaccines are another significant segment in the market. Protein-based vaccines utilize specific proteins or peptides to stimulate an immune response and confer immunity against infectious diseases. The global focus on vaccination programs, the emergence of new infectious diseases, and the need for improved vaccine technologies drive market growth in this segment.
Besides, protein diagnostics involves using proteins or protein-based assays for diagnostic purposes. These diagnostics can detect specific proteins or biomarkers associated with diseases, aiding in early detection, disease monitoring, and personalized treatment. The growing demand for accurate and reliable diagnostic tools fuels the growth of protein diagnostics and contributes to the overall market.
Breakup by Region:

• North America
o United States
o Canada
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Indonesia
o Others
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Russia
o Others
• Latin America
o Brazil
o Mexico
o Others
• Middle East and Africa

North America exhibits a clear dominance, accounting for the largest protein therapeutics market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.
North America, particularly the United States, holds a significant market share. The region benefits from advanced healthcare infrastructure, a strong presence of biopharmaceutical companies, and robust research and development activities. The presence of key players and extensive investments in protein therapeutics research contribute to market growth in North America. Additionally, the high prevalence of chronic diseases, a large aging population, and favorable reimbursement policies further drive the market in the region.
On the other hand, Asia Pacific is emerging as a rapidly growing market. The region has a large population base, increasing healthcare expenditure, and a rising prevalence of chronic diseases. Countries such as China, Japan, and India are witnessing substantial growth in the biopharmaceutical industry and investing in research and development. Moreover, the increasing awareness of personalized medicine and growing demand for cost-effective treatment options are driving the adoption of protein therapeutics in Asia Pacific.
Competitive Landscape:
Top companies are investing heavily in scientific research to identify new therapeutic targets and develop protein-based drugs with enhanced efficacy and safety profiles. They leverage their protein engineering, molecular biology, and biotechnology expertise to design and optimize therapeutic proteins. Furthermore, these companies establish strategic collaborations with academic institutions, research organizations, and other pharmaceutical companies to access new technologies, expand their pipelines, and accelerate development. Collaborations enable the exchange of knowledge, resources, and expertise, fostering innovation and driving the market. Moreover, successful commercialization strategies play a vital role in driving market growth. These companies employ robust marketing and sales efforts to promote and distribute their products to healthcare providers and patients worldwide. They conduct extensive clinical trials, generate compelling clinical data, and obtain regulatory approvals to ensure market access. Additionally, the top companies continuously invest in manufacturing capabilities and quality control systems to meet the growing demand and ensure a consistent supply of their products. This commitment to manufacturing excellence helps them meet the needs of patients, healthcare providers, and payers, further driving the market growth.
The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:
• Amgen Inc.
• Abbott Laboratories
• Abbvie Inc.
• Baxter International Inc.
• Biogen Inc.
• Csl Behring L.L.C. (CSL Limited)
• Eli Lilly and Company
• F. Hoffmann-La Roche AG (Roche Holding AG)
• Johnson & Johnson
• Merck & Co. Inc.
• Novo Nordisk A/S (Novo Holdings A/S)
• Pfizer Inc.
Recent Developments:
• In 2020, Amgen Inc. entered into a collaboration with Adaptive Biotechnologies to develop and commercialize fully human-neutralizing antibodies targeting SARS-CoV-2, the virus that causes COVID-19.
• In 2021, Abbott Laboratories received FDA clearance for their Tendyne Transcatheter Mitral Valve Replacement (TMVR) system, a minimally invasive therapy for patients with severe mitral regurgitation.
• In 2020, AbbVie Inc. acquired Allergan, a pharmaceutical company known for its portfolio of aesthetic and therapeutic products, including Botox.

Key Questions Answered in This Report
1. What was the size of the global protein therapeutics market in 2023?
2. What is the expected growth rate of the global protein therapeutics market during 2024-2032?
3. What has been the impact of COVID-19 on the global protein therapeutics market?
4. What are the key factors driving the global protein therapeutics market?
5. What is the breakup of the global protein therapeutics market based on the product?
6. What is the breakup of the global protein therapeutics market based on the therapy area?
7. What are the key regions in the global protein therapeutics market?
8. Who are the key players/companies in the global protein therapeutics market?

ページTOPに戻る

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Protein Therapeutics Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Product
6.1 Monoclonal Antibodies (mAbs)
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Human Insulin
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Erythropoietin
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Clotting Factors
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Fusion Protein
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Others
6.6.1 Market Trends
6.6.2 Market Forecast
7 Market Breakup by Therapy Area
7.1 Metabolic Disorders
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Immunological Disorders
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Hematological Disorders
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Cancer
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Hormonal Disorders
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Genetic Disorders
7.6.1 Market Trends
7.6.2 Market Forecast
7.7 Others
7.7.1 Market Trends
7.7.2 Market Forecast
8 Market Breakup by Function
8.1 Enzymatic and Regulatory Activity
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Special Targeting Activity
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Vaccines
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Protein Diagnostics
8.4.1 Market Trends
8.4.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Amgen Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Abbott Laboratories
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Abbvie Inc.
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Baxter International Inc.
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 Biogen Inc.
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 Csl Behring L.L.C. (CSL Limited)
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.7 Eli Lilly and Company
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 F. Hoffmann-La Roche AG (Roche Holding AG)
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 SWOT Analysis
14.3.9 Johnson & Johnson
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials
14.3.9.4 SWOT Analysis
14.3.10 Merck & Co. Inc.
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
14.3.10.4 SWOT Analysis
14.3.11 Novo Nordisk A/S (Novo Holdings A/S)
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.11.3 Financials
14.3.11.4 SWOT Analysis
14.3.12 Pfizer Inc.
14.3.12.1 Company Overview
14.3.12.2 Product Portfolio
14.3.12.3 Financials
14.3.12.4 SWOT Analysis
List of Figures
Figure 1: Global: Protein Therapeutics Market: Major Drivers and Challenges
Figure 2: Global: Protein Therapeutics Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Protein Therapeutics Market: Breakup by Product (in %), 2023
Figure 4: Global: Protein Therapeutics Market: Breakup by Therapy Area (in %), 2023
Figure 5: Global: Protein Therapeutics Market: Breakup by Function (in %), 2023
Figure 6: Global: Protein Therapeutics Market: Breakup by Region (in %), 2023
Figure 7: Global: Protein Therapeutics Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 8: Global: Protein Therapeutics (Monoclonal Antibodies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 9: Global: Protein Therapeutics (Monoclonal Antibodies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 10: Global: Protein Therapeutics (Human Insulin) Market: Sales Value (in Million US$), 2018 & 2023
Figure 11: Global: Protein Therapeutics (Human Insulin) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 12: Global: Protein Therapeutics (Erythropoietin) Market: Sales Value (in Million US$), 2018 & 2023
Figure 13: Global: Protein Therapeutics (Erythropoietin) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 14: Global: Protein Therapeutics (Clotting Factors) Market: Sales Value (in Million US$), 2018 & 2023
Figure 15: Global: Protein Therapeutics (Clotting Factors) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 16: Global: Protein Therapeutics (Fusion Protein) Market: Sales Value (in Million US$), 2018 & 2023
Figure 17: Global: Protein Therapeutics (Fusion Protein) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 18: Global: Protein Therapeutics (Other Products) Market: Sales Value (in Million US$), 2018 & 2023
Figure 19: Global: Protein Therapeutics (Other Products) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 20: Global: Protein Therapeutics (Metabolic Disorders) Market: Sales Value (in Million US$), 2018 & 2023
Figure 21: Global: Protein Therapeutics (Metabolic Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 22: Global: Protein Therapeutics (Immunological Disorders) Market: Sales Value (in Million US$), 2018 & 2023
Figure 23: Global: Protein Therapeutics (Immunological Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 24: Global: Protein Therapeutics (Hematological Disorders) Market: Sales Value (in Million US$), 2018 & 2023
Figure 25: Global: Protein Therapeutics (Hematological Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 26: Global: Protein Therapeutics (Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 27: Global: Protein Therapeutics (Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 28: Global: Protein Therapeutics (Hormonal Disorders) Market: Sales Value (in Million US$), 2018 & 2023
Figure 29: Global: Protein Therapeutics (Hormonal Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 30: Global: Protein Therapeutics (Genetic Disorders) Market: Sales Value (in Million US$), 2018 & 2023
Figure 31: Global: Protein Therapeutics (Genetic Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 32: Global: Protein Therapeutics (Other Therapy Areas) Market: Sales Value (in Million US$), 2018 & 2023
Figure 33: Global: Protein Therapeutics (Other Therapy Areas) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 34: Global: Protein Therapeutics (Enzymatic and Regulatory Activity) Market: Sales Value (in Million US$), 2018 & 2023
Figure 35: Global: Protein Therapeutics (Enzymatic and Regulatory Activity) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 36: Global: Protein Therapeutics (Special Targeting Activity) Market: Sales Value (in Million US$), 2018 & 2023
Figure 37: Global: Protein Therapeutics (Special Targeting Activity) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 38: Global: Protein Therapeutics (Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
Figure 39: Global: Protein Therapeutics (Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 40: Global: Protein Therapeutics (Protein Diagnostics) Market: Sales Value (in Million US$), 2018 & 2023
Figure 41: Global: Protein Therapeutics (Protein Diagnostics) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 42: North America: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 43: North America: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 44: United States: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 45: United States: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 46: Canada: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 47: Canada: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 48: Asia Pacific: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 49: Asia Pacific: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 50: China: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 51: China: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 52: Japan: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 53: Japan: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 54: India: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 55: India: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 56: South Korea: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 57: South Korea: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 58: Australia: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 59: Australia: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 60: Indonesia: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 61: Indonesia: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 62: Others: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 63: Others: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 64: Europe: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 65: Europe: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 66: Germany: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 67: Germany: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 68: France: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 69: France: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 70: United Kingdom: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 71: United Kingdom: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 72: Italy: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 73: Italy: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 74: Spain: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 75: Spain: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 76: Russia: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 77: Russia: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 78: Others: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 79: Others: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 80: Latin America: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 81: Latin America: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 82: Brazil: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 83: Brazil: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 84: Mexico: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 85: Mexico: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 86: Others: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 87: Others: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 88: Middle East and Africa: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 89: Middle East and Africa: Protein Therapeutics Market: Breakup by Country (in %), 2023
Figure 90: Middle East and Africa: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 91: Global: Protein Therapeutics Industry: SWOT Analysis
Figure 92: Global: Protein Therapeutics Industry: Value Chain Analysis
Figure 93: Global: Protein Therapeutics Industry: Porter’s Five Forces Analysis
List of Tables
Table 1: Global: Protein Therapeutics Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Protein Therapeutics Market Forecast: Breakup by Product (in Million US$), 2024-2032
Table 3: Global: Protein Therapeutics Market Forecast: Breakup by Therapy Area (in Million US$), 2024-2032
Table 4: Global: Protein Therapeutics Market Forecast: Breakup by Function (in Million US$), 2024-2032
Table 5: Global: Protein Therapeutics Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 6: Global: Protein Therapeutics Market Structure
Table 7: Global: Protein Therapeutics Market: Key Players